The phase 2 obesity trial and MASLD substudy included 1 mg, 4 mg, 8 mg, and 12 mg once-weekly subcutaneous retatrutide [4], [6]
It's the rapid weight loss itself that shocks the system, not a direct drug toxicity to follicles
Dietary modifications and supportive therapies may also be necessary to manage symptoms and prevent complications
Ensure you understand any exclusions related to weight loss services, off-label use, or compounding
It is not approved by the FDA for human consumption, veterinary use, or any therapeutic application
removing the medication allows those neural patterns to revert